AnaptysBio Posts $49.6 Million Net Income in Q4
ANAB has more than doubled off its 52-week low of $13.99.
Summary
AnaptysBio announced its fourth-quarter financial results, reporting a net income of $49.614 million. The company also posted collaboration revenue of $108.249 million and income from operations of $66.901 million. These figures provide key insights into the company's recent financial performance. While the headline provides specific numbers, it does not indicate whether these results met, exceeded, or fell short of analyst consensus estimates, which is crucial for immediate stock price reaction. Traders will be analyzing these raw numbers and awaiting further context from the full earnings report.
At the time of this announcement, ANAB was trading at $52.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $13.99 to $57.74. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.